263 related articles for article (PubMed ID: 19377072)
1. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.
Farina L; Carniti C; Dodero A; Vendramin A; Raganato A; Spina F; Patriarca F; Narni F; Benedetti F; Olivieri A; Corradini P
Haematologica; 2009 May; 94(5):654-62. PubMed ID: 19377072
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
Ritgen M; Stilgenbauer S; von Neuhoff N; Humpe A; Brüggemann M; Pott C; Raff T; Kröber A; Bunjes D; Schlenk R; Schmitz N; Döhner H; Kneba M; Dreger P
Blood; 2004 Oct; 104(8):2600-2. PubMed ID: 15205268
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Dreger P; Döhner H; Ritgen M; Böttcher S; Busch R; Dietrich S; Bunjes D; Cohen S; Schubert J; Hegenbart U; Beelen D; Zeis M; Stadler M; Hasenkamp J; Uharek L; Scheid C; Humpe A; Zenz T; Winkler D; Hallek M; Kneba M; Schmitz N; Stilgenbauer S;
Blood; 2010 Oct; 116(14):2438-47. PubMed ID: 20595516
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC; Zhang B; Narasimhan B; Carlton V; Zheng J; Moorhead M; Krampf MR; Jones CD; Waqar AN; Faham M; Zehnder JL; Miklos DB
Leukemia; 2013 Aug; 27(8):1659-65. PubMed ID: 23419792
[TBL] [Abstract][Full Text] [Related]
8. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
9. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
10. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
12. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
13. [The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
Sidorova IuV; Sorokina TV; Biderman BV; Nikulina EE; Kisilichina DG; Naumova EV; Pochtar' ME; Lugovskaia SA; Ivanova VL; Kovaleva LG; Ptushkin VV; Nikitin EA; Sudarikov AB
Klin Lab Diagn; 2011 Dec; (12):22-4, 33-5. PubMed ID: 22416427
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Machaczka M; Johansson JE; Remberger M; Hallböök H; Malm C; Lazarevic VLj; Wahlin A; Omar H; Juliusson G; Kimby E; Hägglund H
Leuk Lymphoma; 2012 Sep; 53(9):1699-705. PubMed ID: 22335529
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
16. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
17. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation.
Liu J; Wang Y; Xu LP; Liu DH; Qin YZ; Chang YJ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):929-36. PubMed ID: 24631740
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
Khouri IF; Lee MS; Romaguera J; Mirza N; Kantarjian H; Korbling M; Albitar M; Giralt S; Samuels B; Anderlini P; Rodriguez J; von Wolff B; Gajewski J; Cabanillas F; Champlin R
Ann Oncol; 1999 Nov; 10(11):1293-9. PubMed ID: 10631455
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P; Tarella C; Olivieri A; Gianni AM; Voena C; Zallio F; Ladetto M; Falda M; Lucesole M; Dodero A; Ciceri F; Benedetti F; Rambaldi A; Sajeva MR; Tresoldi M; Pileri A; Bordignon C; Bregni M
Blood; 2002 Jan; 99(1):75-82. PubMed ID: 11756155
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
